← back to search

Alessandra Biffi

Dana-Farber/Boston Children's Cancer and Blood Disorders Center · IT
Area of research
Physiology · Genetics
Research interest
Research interests include Lysosomal Storage Disorders Research, Virus-based gene therapy research, Acute Lymphoblastic Leukemia research, and Childhood Cancer Survivors' Quality of Life.
h-index
44
citations
10,887
works
275
NIH funding
primary concept
Medicine
email

Recent publications

Central nervous system disorders following haematopoietic stem cell transplantation: a prospective case–control observational study from the Infectious Diseases Working Party and the Transplant Complications Working Party of EBMT
EClinicalMedicine 2026cited by 2position: middledoi
Restoration of progranulin by engineered hematopoietic stem cell-derived microglia corrects phenotypes of granulin knockout mice.
2026cited by 1position: contributordoi
Outcome of second conditioned allogeneic stem cell transplant in children with non-SCID inborn errors of immunity
Blood Advances 2026cited by 0position: middledoi
CD84 is a specific target for acute myeloid leukemia CAR-T cell therapy.
2026cited by 0position: contributordoi
The impact of pre-transplant extramedullary disease on the outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukaemia in children- on behalf of PDWP/EBMT.
2026cited by 0position: contributordoi
Outcome of second conditioned allogeneic stem cell transplant in children with non-SCID inborn errors of immunity.
2026cited by 0position: contributordoi
Comparison of outcomes of BuCy versus BuCyMel as preparation for allogeneic HSCT in infants with acute myeloid leukemia in first complete remission: a multicenter study from the EBMT PDWP.
2026cited by 0position: contributordoi
A survey on the practices and the management of hemorrhagic cystitis in patients who undergo allogeneic hematopoietic stem cell transplantation, on behalf of the Infectious Diseases Working Party of EBMT
Bone Marrow Transplantation 2025cited by 1position: middledoi
Real-Life Use of Posaconazole in Clinical Practice for Onco-Hematological Children: A National Survey by AIEOP Infectious Diseases Working Group
Journal of Fungi 2025cited by 1position: middledoi
The Impact of Pre-Transplant Extramedullary Disease on the Outcome of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Children- on Behalf of PDWP/EBMT
Research Square 2025cited by 0position: middledoi
Comparison of outcomes of BuCy versus BuCyMel as preparation for allogeneic HSCT in infants with acute myeloid leukemia in first complete remission: a multicenter study from the EBMT PDWP
Bone Marrow Transplantation 2025cited by 0position: middledoi
Comparison of outcomes in pediatric patients with acute leukemia undergoing allogeneic HLA-haploidentical hematopoietic stem cell transplantation (HSCT) after in vitro a/b T- and CD19-cell depletion or In Vivo administration of post-transplant cyclophosphamide: An EBMT pediatric working party study
Blood 2025cited by 0position: middledoi
Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy.
2025cited by 0position: contributordoi
A survey on the practices and the management of hemorrhagic cystitis in patients who undergo allogeneic hematopoietic stem cell transplantation, on behalf of the Infectious Diseases Working Party of EBMT.
2025cited by 0position: contributordoi
The Impact of Pre-Transplant Extramedullary Disease on the Outcome of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Children- on Behalf of PDWP/EBMT
2025cited by 0position: contributordoi
Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP)
Bone Marrow Transplantation 2024cited by 29position: middledoi
Outcomes of HLA-mismatched HSCT with TCRαβ/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity
Blood 2024cited by 21position: middledoi
Matched unrelated donor transplantation versus haploidentical transplantation with post-transplant cyclophosphamide in children with acute myeloid leukemia: a PDWP-EBMT study
Haematologica 2024cited by 15position: middledoi
Outcomes of HLA-mismatched HSCT with TCRαβ/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity.
2024cited by 11position: contributordoi
Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study
Bone Marrow Transplantation 2024cited by 8position: middledoi
CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment.
2024cited by 8position: contributordoi
Therapeutic efficacy of intracerebral hematopoietic stem cell gene therapy in an Alzheimer's disease mouse model.
2024cited by 6position: contributordoi
Haploinsufficiency at the CX3CR1 locus of hematopoietic stem cells favors the appearance of microglia-like cells in the central nervous system of transplant recipients
Nature Communications 2024cited by 4position: lastdoi
An empowered, clinically viable hematopoietic stem cell gene therapy for the treatment of multisystemic mucopolysaccharidosis type II
Molecular Therapy 2024cited by 2position: contributordoi
Haploinsufficiency at the CX3CR1 locus of hematopoietic stem cells favors the appearance of microglia-like cells in the central nervous system of transplant recipients.
2024cited by 1position: contributordoi
An innovative hematopoietic stem cell gene therapy approach benefits CLN1 disease in the mouse model.
2023cited by 8position: contributordoi
Long-term proliferation of immature hypoxia-dependent JMML cells supported by a 3D in vitro system.
2023cited by 2position: contributordoi
Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access
The Lancet 2022cited by 279position: middledoi
Hypogammaglobulinemia in Children After Hematopoietic Stem Cell Transplantation and Rituximab Treatment: Relevance of B Cell Subsets
Journal of Pediatric Hematology/Oncology 2022cited by 5position: middledoi
Specific Cytogenetic Abnormalities at Diagnosis Predict Survival after Hematopoietic Cell Transplant in Poor-Risk Pediatric Acute Myeloid Leukemia: A PDWP/EBMT Study
Blood 2022cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 17 papers (2020–2026)Franca Fagioli · Infant6 papers (2020–2026)Robert Wynn · Manchester University NHS Foundation Trust4 papers (2019–2026)Franco Locatelli · Bambino Gesù Children's Hospital4 papers (2025–2026) · 4 papers (2025–2026)Luca Biasco · Institute of Infection and Immunity3 papers (2012–2019)Birgit Burkhardt · University Hospital Bonn3 papers (2022–2026)Maura Faraci · Istituto Giannina Gaslini3 papers (2024–2026)Katia Perruccio · Ospedale Santa Maria3 papers (2024–2025)Marc Bierings · Beatrix Kinderziekenhuis3 papers (2022–2026)Miguel Ángel Díaz · Universitat Politècnica de València3 papers (2022–2026)Jacques-Emmanuel Galimard · Sorbonne Paris Cité3 papers (2025–2026)Marco Zecca · Istituti di Ricovero e Cura a Carattere Scientifico3 papers (2023–2026)Krzysztof Kalwak · Children's Memorial Health Institute3 papers (2025–2026)Annita Montepeloso · Dana Farber/Boston Children’s cancer and Blood Disorders3 papers (2024–2024)Franco Locatelli · Assistance Publique – Hôpitaux de Paris2 papers (2022–2024) · 2 papers (2012–2021)Christian Brendel · Harvard Stem Cell Institute2 papers (2019–2020) · 2 papers (2024–2025)Antonio Marzollo · University of Padua2 papers (2021–2022)